Intuniv is a new non-stimulant medication for the treatment of children and teens with ADHD. Intuniv is an extended-release form of guanfacine (Tenex).
Intuniv is used to treat children and teens with ADHD. However, Intuniv has not yet been approved by the FDA. The manufacturer has received an "approvable letter" from the FDA, which is often a big step in getting a medicine approved and many experts believe it will be approved soon.
- Intuniv was formally known as GXR and SPD503
- It is a selective alpha-2A-receptor agonist
- Like Strattera, another non-stimulant for ADHD, Intuniv is not a controlled substance, which can making getting refills easier for parents
Until more is known about Intuniv, the first benefit is that there will simply be another option for treating children with ADHD. This is especially important as Intuniv offers another non-stimulant treatment option for children who don't tolerate medicines such as Ritalin, Concerta, Adderall XR, Focalin XR, or Vyvanse.
Intuniv will be available as a pill in four dosage strengths, including 1mg, 2mg, 3mg, and 4mg.
Side effects of Intuniv include somnolence (drowsiness), fatigue, abdominal pain, and headache.
- Intuniv is being marketed by Shire, the same company that makes Adderall XR, Vyvanse, and Daytrana.
- Although Tenex is used to treat high blood pressure, it is already a second-line treatment for ADHD.
Source:
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Biederman J - Pediatrics - 01-JAN-2008; 121(1): e73-84.
